We have developed a waveguide-based optical biosensor for the sensitive and specific detection of biomarkers associated with disease. Our technology combines the superior optical properties of single-mode planar waveguides, the robust nature of functionalized self-assembled monolayer sensing films and the specificity of fluorescence sandwich immunoassays to detect biomarkers in complex biological samples such as serum, urine and sputum. We have previously reported the adaptation of our technology to the detection of biomarkers associated with breast cancer and anthrax. However, these approaches primarily used phospholipid bilayers as the functional film and organic dyes (ex: AlexaFluors) as the fluorescence reporter. Organic dyes are easily photodegraded and are not amenable to multiplexing because of their narrow Stokes' shift. Here we have developed strategies for conjugation of the detector antibodies with quantum dots for use in a multiplex detection platform. We have previously evaluated dihydroxylipoic acid quantum dots for the detection of a breast cancer biomarker. In this manuscript, we investigate the detection of the Bacillus anthracis protective antigen using antibodies conjugated with polymer-coated quantum dots. Kinetics of binding on the waveguide-based biosensor is reported. We compare the sensitivity of quantum dot labeled antibodies to those labeled with AlexaFluor and demonstrate the photostability of the former in our assay platform. In addition, we compare sulfydryl labeling of the antibody in the hinge region to that of nonspecific amine labeling. This is but the first step in developing a multiplex assay for such biomarkers on our waveguide platform.
INTRODUCTION:
Anthrax is a deadly acute disease of humans and animals caused by Bacillus anthracis, an encapsulated spore-forming gram-positive bacterium. The bacterium can persist in the environment for elongated periods of time and hence, eradication of the disease is difficult. Humans can become infected when exposed to the pathogen by one of three routes: inhalational, cutaneous or systemic, of which inhalational anthrax is the most deadly. The infectivity of the bacterium, combined with its persistence as a spore, has resulted in development of anthrax as a bioweapon. The 2001 mailing and subsequent spread of Bacillus anthracis spores in the United States, resulted in five deaths and left 17 individuals infected with the disease. Unfortunately, anthrax was confirmed in only one of the five individuals before death, suggesting that current methods of detection and diagnosis of the disease are not rapid enough to detect bioagents and initiate effective therapy.
The major virulence factor of Bacillus anthracis is the anthrax toxin 1 . The toxin causes septicemia and death in the infected host. The toxin is comprised of three major proteins: protective antigen (PA), lethal factor (LF) and edema factor (EF). Binding of PA to receptors on host macrophages triggers an endocytotic event resulting in the internalization of EF and LF. Once internalized, LF, a matrix metalloproteinase disrupts cellular signal cascades. EF, on the other hand, is a calmodulin activated adenylate cyclase that causes an increase in intracellular cyclic AMP and hence, edema. The disruption of signal transduction cascades results in septic shock and cell death.
The sensor team at the Los Alamos National Laboratory (LANL) has developed a waveguide-based biosensor for the sensitive, specific and rapid detection of biomarkers associated with disease. Our technology uses functionalized planar optical waveguides that are functionalized either with phospholipids bilayers 2,3 or self-assembled monolayers (SAMs) 4 and assembled in a flow cell. Coupling of light into gratings etched on the waveguide allows for its propagation by total internal reflection. Much of the light stays within the guided mode. However, a small portion, the evanescent field, leaks out. This field is extremely bright at the surface of the waveguide and is completely eliminated at a distance of 200-400 nm from the surface. This decay allows for sensitive biodetection within the evanescent field, and little background fluorescence, thereby minimizing nonspecific binding (NSB) in complex biological samples (e.g. serum and urine). Further reduction of NSB comes from the use of SAMs as the functional surface. These surfaces, developed by our team, are also robust, stable for long time periods and can be washed with detergents 4 . Our first demonstration of the feasibility of this platform for bioassays was, in fact, an assay for the anthrax PA 2 . Although a sensitive assay for the antigen was developed with a limit of detection (LoD) of 1 pM, the assay used organic dyes (AlexaFluors) as the fluorescence reporter. Organic fluorophores are easily photobleached and multiple dyes cannot be excited by the same excitation source, thus limiting them for simple multiplex excitation.
Quantum dots (QDs) are fluorescent semiconductor nanocrystals that have been extensively used for bioapplications 5, 6, 7 . They are intrinsically more photostable than organic dyes. QDs have a broad Stokes' shift, which allows the simultaneous excitation of multiple QDs at a single wavelength. This makes them extremely exciting candidates for use in multiplex detection platforms. Although QDs have been extensively used in bio-imaging, immunohistochemistry and other bio-applications, their use in immunoassays is rather limited 7 . We have previously conjugated dihydroxylipoic acid (DHLA) QDs to antibodies and evaluated them in the biodetection of carcinoembryonic antigen, a breast cancer biomarker 3 . However, DHLA QDs have low quantum efficiency and hence, the resolution of the assay was poor than that obtained with organic dyes. In this manuscript, we present for the first time, the conjugation of antibodies for PA with polymer encapsulated QDs and their successful evaluation in a sandwich immunoassay on our biosensor. In addition to traditional amine labeling, we also evaluated the labeling of antibodies with QDs in the hinge region (thiol-labeling), a strategy we previously evaluated with organic dyes for superior signal amplification 3 . Finally, we have explored the kinetics of antibody-QD binding to PA. This is but the first step in the development of a multiplex assay for anthrax toxins. We are in the process of evaluating a sandwich assay for lethal factor using an antibody with a different QD. Initial evaluations are promising and we hope to transition these assays to a multiplex format for the simultaneous detection of these antigens.
MATERIALS AND METHODS
2. 1 Materials: Purified antibodies (mouse monoclonal, IgG1, human adsorbed) that bind orthogonal epitopes of the anthrax PA (anti-PA antibody BAP106 for capture and BAP105 as reporter) were obtained from QED Bioscience Inc. We have previously documented the ability of these antibodies to form an effective sandwich by binding orthogonal epitopes of PA 2, 4 . Amino-functionalized QD (655 nm, QD655), Qdot®655 ITK TM carboxyl quantum dots and AF647-Nhydroxysuccinimide (NHS) ester labeling kits and 96 well plates were from Invitrogen. Biotinylation, protein estimation and electrophoresis reagents were obtained from Pierce. Tri-n-octylphosphine oxide (TOPO) and tri-n-octylphosphorine (TOP) capped CdSe/ZnS core/shell QDs were a generous gift from Dr. J. Hollingsworth (LANL). Gel filtration columns and spin filters were from Harvard Apparatus. Buffers, chemicals, immunoblot materials and other components were purchased from Sigma Aldrich or Fisher Scientific. Waveguides were obtained from nGimat, Atlanta, GA. 1,2-dioleoylsn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(cap biotinyl) (sodium salt) were purchased from Avanti Polar Lipids. Materials required for SAM preparation are listed in detail elsewhere 4 .
Methods: Preparation of Antibodies:
The capture antibodies were modified by biotinylation to allow their immobilization on the waveguide surface. The detailed protocols for antibody biotinylation have been described before (2, 3). Carboxyl QD605 or QD655 stock (70 μl, 8 μM, Invitrogen), diluted with 500 μl borate buffer (10 mM at pH7.3) was mixed with 200 μg anti-PA or anti-LF antibody, respectively, in the presence of aqueous N-ethyl-N'-dimethylaminopropyl-carbodiimide (EDC) and reacted at room temperature for 1.5 hours. The reaction was quenched by addition of borate buffer (500 μl, 50 mM at pH9.0) and incubated at 4 °C overnight, then washed five cycles with 1mL borate buffer (25 mM at pH7.5) using 100 kDa MWCO spin filter. The reaction mixtures were then passed through the 1000 kDa MWCO spin filter. For preparation of QD655-EMCS, QD655-PEG-NH 2 (40 μl, 8.0 μM) was diluted into 400 μl with borate buffer (10 mM at pH7.5) and mixed with sulfo-EMCS ( 6.4 μl, 10 mM) and stirred at room temperature for 2 hours. The reaction mixture was then washed 3 times 400 μl with borate buffer (10 mM at pH7.5) and concentrated to final 200 μl. The anti-PA antibody-SH was then reduced at the hinge region. For this, the antibody (60 μl, 1 mg/ml) was added TCEP (6 μl, 10 mM) and incubated at RT for 2 hours. Then the reaction mixture passed through Sephadex G25 spin column to remove the unreacted TCEP and other small molecules. QD655-EMCS (100 μl) was finally mixed with above reduced anti-PA-SH and reacted at overnight and RT and clarified by filtration (Millipore 0.25 μm).
Detection of the Labeled Material using Fluorescence Immunoassays:
The antibodies were first tested in a standard plate-based immunoassay format. Capture antibody [50 nM] was coated on a 96 well plate for 2 hrs at room temperature (RT). The plates were then blocked for 2 hrs with 4.5% fish gelatin. Antigen was added in increasing concentrations and incubated overnight at 4°C. Unbound antigen was removed by washing with PBS containing 0.01% tween 20. The plates were then washed three times with PBS and fluorescently labeled reporter antibody was added and incubated (2 hrs, RT). Following washing, the specific signal was measured using a TECAN Sapphire fluorescence plate reader. NSB of the reporter antibody in the absence of the antigen was measured as control.
Preparation of the Flow Cell and Waveguide-Assay Protocol:
The detailed protocol for waveguide cleaning and functionalization with biotinylated (0.1%) SAMs 3, 4 have been described before. Once functionalized, the waveguide is assembled in a flow cell. Neither stabilization nor blocking is required for use of SAMs. Once assembled, the waveguide-associated parameters such as coupled power and waveguide background are measured for all experiments. Subsequently, 10 pM of fluorescently labeled streptavidin is added to the flow cell. After a 5 min incubation, unbound streptavidin is washed and specific signal due to binding of the fluorescently labeled streptavidin to the biotinylated SAMs is measured as an indicator of system performance and SAM viability. This signal is completely photobleached (2 min exposure). Following saturation of the functional surface with unlabeled streptavidin, the biotinylated capture antibody is added (80 nM). Following a 5 min incubation, unbound antibody is washed from the surface. NSB is determined when the fluorescently labeled reporter antibody is added on the functional surface in the absence of the antigen. This is typically < 500 RFU (Figures 2, 3) . The antigen is then added and incubated for 5 min, followed again by the reporter antibody and the specific signal is measured after a wash step to remove unbound components.
RESULTS:
The QD amine-labeled antibodies were used for the detection of PA in a plate-based sandwich immunoassay. This protocol is comparable to a typical ELISA using a QDs as the fluorescence reporter. As indicated in Figure 1 , the LoD is 130 pM using this strategy. The assay saturates between 1-5 nM of PA using this approach.
Using the same antibodies, we performed a sandwich assay for the detection of PA using the waveguide-based biosensor. The preliminary experiments were performed at 100 pM PA, which is slightly below the LoD of the antigen using the plate-based format (Figure 1 ). As indicated in Figure 2 , the waveguide-associated background (a measure of intrinsic impurities in the waveguide itself) is very low (<10 RFU). NSB of the fluorescent reporter to the functionalized waveguide surface in the absence of the antigen was found to be ~40 RFU. Specific binding of PA [100 pM] resulted in a signal of ~ 814 RFU using this assay. This results in a signal/noise of 20.4, where the noise is the NSB measured (~40 RFU). It is clear from this data that the LoD and sensitivity of the waveguide-based assay for PA is much better than that obtained in conventional plate-based assays using similar fluorescence reporters. We also measured the photostability of our QD conjugated antibodies by exciting it at 532 nm for 2 min followed by a measurement. As indicated in Figure 2 , there is little or no loss in signal intensity after 2 min under the conditions used for the assay (input power is 440 μW). Figure 3 demonstrates the increase in signal associated with increase in concentrations of PA using the waveguide approach. This is not a concentration curve for the antigen as all measurements were performed on the same waveguide in sequence and a linear response is not expected. This is simply a demonstration of the sensitivity of the assay and the ability to quantitatively measure varying concentrations of the antigen. 1 pM PA was easily detected with a signal/noise of ~ 4.0. The signal/noise for detection of 100 pM PA is ~13. This is slightly lower than that seen in Figure  2 . However, waveguides are intrinsically different from each other with respect to their optical properties and functional surface and this may account for this difference.
The binding time (kinetics of saturation) of the QD labeled reporter under current experimental conditions was evaluated ( Figure 4) . As mentioned earlier, only molecules within the evanescent field of the waveguide (< 200 nm) are detected with our approach. This allows for a separation of surface bound components from solution contaminants. This optical property, in combination with the photostability of the QD-coated reporter, was harnessed for determination of the binding time. As indicated in Figure 4 , the specific signal increased steadily for about 400 seconds after antibody addition and then saturated. Following this, any unbound antibody (non-specific aggregation to the surface) was removed by washing with PBS. This resulted in a slight decrease in signal intensity. This experiment demonstrates that the antigen-antibody binding saturates within 10 minutes under the conditions used.
We have previously evaluated hinge labeling of our antibodies with both DHLA QDs and with organic dyes 3 . We used a similar strategy here with the polymer coated QDs. Interestingly, labeling polymer-coated QDs in the hinge region of the anti-PA antibody results in a complete loss of functionality of the antibody ( Figure 5 ). We validated this result with a second preparation of the antibody. It is possible that this conjugation alters the conformation of the antibody and prevents its binding to PA. The fluorescence of the antibody was maintained, as measured by UV-Vis spectrometery. Polyacrylamide gel electrophoresis confirmed that the antibody was indeed labeled with the QD. Whereas the unlabeled antibody demonstrated bioactivity by plate-based immunoassay (Figure 1) , there was no bioactivity measured with the conjugate. This lack of activity was also confirmed by immunoblot analysis.
DISCUSSION:
No single biomarker can accurately predict disease. Therefore, the ability to multiplex is required for efficient use of biomarkers in bio-detection and diagnosis. Our team has developed a waveguide-based biosensor for the sensitive, specific and rapid detection of biomarkers associated with disease. We have previously adapted this technology to the detection of biomarkers associated with breast cancer 3 , influenza 8 , anthrax 2 and tuberculosis. Most of these assays were performed using organic dyes as the fluorescent label. In this manuscript we demonstrate the use of QDs as a photostable fluorescence reporter for the detection of PA using our waveguide-based platform. This is the first step towards using QDs for multiplex detection of antigens. This is because QDs are intrinsically photostable. Also, because they have a broad Stoke's shift, several QDs can be simultaneously excited with the same wavelength and emit at different wavelengths depending on their size. This tuneability can be harnessed for multiplex detection of antigens. In fact, it has been suggested that this application is where QDs will find their maximal utility in the near future 7 . In this manuscript, we have successfully developed a antibody-QD conjugate and used it in a sandwich immunoassay format. Our assay, using our optical biosensor, is much more sensitive than standard plate based immunoassays using the same materials (Figure 1 vs. Figures 2 and 3) . Also, using the waveguide allows for minimization of NSB associated with complex samples and hence, makes adaptation of the platform to diagnostic approaches easier. We are currently developing a multiplex assay for PA and LF on our biosensor. In addition, we are also developing a multichannel waveguide for the simultaneous detection of several samples. This will allow for the sensitive, specific, rapid and quantitative detection of analytes. This is critical for efficient diagnosis and detection of infection, especially in the event of biowarfare and biosecurity threats.
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